The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Have a look at TILS - the directors totally messed that up
I hold 690k of Okyo in Crest.
I
I bought at an average of 4.8p so down quite a bit.I do think that this company will do very well in the future.Been dabbling on the stock market for a number of years, but this is the first time I'v experienced moving the whole company dealing to the USA.Does anyone know if it's difficult to deal with the Dow ?Information will be welcomed.
With their intention of delisting from the aim & also consolidating the shares, this company is a sell for anyone holding in certificate form. Complex to get reissued in a proper holding online, it's advised to sell up now & just accept any loss. Reinvesting any monies in Genedrive will for sure benefit your wealth.
what happens to the shares we hold?
another stitch up PI company by Gabriele Cerrone
G.C. Filling his boots :-)
1 Nasdaq share for every 65 ordinary shares. Although there always appears to be a slightly higher comparative price in the US
Hi
Can anyone please explain why price difference at london stock exchange 2.75 and nasdaq 1.55/
Thanks
Dry Eye Disease is certainly very common, and certainly as a GP I used to see a couple of cases a week.
The science here looks pretty solid, and with clinical trials due to start any day now things are starting to get exciting.
....Still slightly concerned at the horrendous spread this trades on (even though you can generally trade well inside this)
A sniff of positive results here and OKYO will really take off!
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren’t Fully Effective – OKYO Pharma’s Drug Candidate Could Be The Solution - OKYO Pharma (NASDAQ:OKYO) - Benzinga
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution | Benzinga
Good Luck Everyone
What the .ell happened there ? It's been Sleepy valley for months.
Not that I could see. I decided to sell my position. Will sit and see what it does next week. Always wary of big moves without news. They so often retrace
Any news here? Huge volume on Nasdaq
@ZaksTradersCafe 20 Small Caps For 2023. The Countdown Begins.
20) OKYO Pharma (#OKYO): 2.75p Target 7p
19) Polarean (#POLX): 49p Target 150p
18) Baron Oil (#BOIL): 0.14p Target 0.3p
17) Hvivo (#HVO): 10p Target 20p
16) GreenX Metals (#GRX): 33p Target 50p
https://twitter.com/Share_Talk/status/1608072972094345217?s=20
Such an accelerated approved clearly means that the costs of development are that much more economic. Finally, given the way that the market cap is back to where it was two years ago, despite the advances made, we should see a realignment in 2023, especially given the drug will be “moving into the clinic in the first quarter of 2023.
https://www.share-talk.com/zak-mir-20-small-caps-for-2023-countdown-20-to-16/
Posted over on ADVFN and very interesting watch:
https://youtu.be/qC6PYmkS4sY
This is the comment that is creating the significant interest, particularly over in the US:
Biotechnology company intends to file a investigational new drug filing to the US Food & Drug Administration of OK-101 for the treatment of Dry Eye Disease......
Possible tap in to Multi-Billion Dollar Market opportunity in the making.
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
· OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
· Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
· IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.
· Multibillion-dollar DED market whose medical needs remain largely unmet.
· AmbioPharm supporting OK-101 program with peptide synthesis and development.
A lot of small bios are valued at cash level or below. I don’t think Okyo has much cash so it is still relatively quite highly valued, which is why I think it is under pressure
Why is this stock dropping off the back of no news and the only recent news was good news ?? I dont get it
Surely to be accepted on the USA stock listing has got to be a good sign and a confidence booster????.
Like I said further back here
What a dog of a share this is, just like the one the bods are attached to ( TILS) Tiziana Life Sciences
lots of attention on the ADS shares listed over the pond today, seen two upward halts already